Compare PJT & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PJT | BLTE |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.1B |
| IPO Year | N/A | 2022 |
| Metric | PJT | BLTE |
|---|---|---|
| Price | $188.59 | $156.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $191.00 | $156.00 |
| AVG Volume (30 Days) | 199.5K | ★ 247.6K |
| Earning Date | 02-03-2026 | 11-10-2025 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | ★ 72.84 | N/A |
| EPS | ★ 6.53 | N/A |
| Revenue | ★ $1,657,789,000.00 | N/A |
| Revenue This Year | $15.24 | N/A |
| Revenue Next Year | $10.85 | N/A |
| P/E Ratio | $28.79 | ★ N/A |
| Revenue Growth | ★ 23.30 | N/A |
| 52 Week Low | $119.76 | $49.00 |
| 52 Week High | $190.28 | $170.25 |
| Indicator | PJT | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 68.15 | 52.81 |
| Support Level | $174.06 | $146.06 |
| Resistance Level | $183.12 | $170.25 |
| Average True Range (ATR) | 5.16 | 8.27 |
| MACD | 1.21 | -2.22 |
| Stochastic Oscillator | 93.18 | 34.98 |
PJT Partners Inc is an advisory-focused investment bank that offers a portfolio of advisory services designed to help its clients achieve their strategic objectives. The company delivers a range of strategic advisory, capital markets advisory, restructuring and special situations, and shareholder advisory services to corporations, financial sponsors, institutional investors, and governments around the world. It also provides private fund advisory and fundraising services for alternative investment strategies, including private equity, real estate, hedge funds, and private credit. The company generates its revenue from advisory fees, placement services and others. Geographically, It generates a majority of its revenue from the United States.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.